fludarabine + bendamustine + mitoxantrone + alemtuzumab

This is a combination regimen of four antineoplastic agents—fludarabine, bendamustine, mitoxantrone, and alemtuzumab—used experimentally or in clinical trials for the treatment of hematologic malignancies such as T-cell prolymphocytic leukemia (T-PLL) and chronic lymphocytic leukemia (CLL). - **Fludarabine** is a purine analog that inhibits DNA synthesis by interfering with DNA polymerase and ribonucleotide reductase. - **Bendamustine** is an alkylating agent with both alkylator and purine analog properties, causing cross-linking of DNA strands leading to cell death. - **Mitoxantrone** is an anthracenedione that intercalates into DNA and inhibits topoisomerase II, resulting in cytotoxicity. - **Alemtuzumab** is a monoclonal antibody targeting CD52 on lymphocytes, inducing cell lysis via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This multi-agent protocol aims to maximize anti-leukemic efficacy by combining different mechanisms of action from chemotherapy (DNA damage/cell cycle inhibition) with immunotherapy (targeted depletion of malignant lymphocytes). The regimen has been studied primarily in relapsed/refractory or high-risk leukemias where standard therapies are insufficient[1][3][5].

Other names

氟达拉滨 + 苯达莫司汀 + 米托蒽醌 + 阿仑珠单抗